References:

Disclosure of Interests: Luca Moroni: None declared, adriana cariddi: None declared, Silvia Sartoirelli: None declared, Emanuel Della Torre: None declared, Tommaso Germanò: None declared, Giuseppe Alvise Ramirez: None declared, Luca Moroni: None declared, adriana cariddi: None declared, Enrica Bozzolo: None declared, Mona-Rita Yacoub: None declared, Lorenzo Dagna Grant/research support from: The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unrestricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI., Consultant of: Dr Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celtrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI.

DOI: 10.1136/annrheumdis-2020-eular.1766

AB0513

GLOMERULONEPHRITIS IN LEVAMISOLE-ADULTERATED COCAINE VASCULOPATHY (LACIV): A 51-CASE SERIES

C. Muñoz1,2,3, J. Daramillo Arroyave1,2,4,5, L. Hernandez2,5, G. Vásquez2, M. Restrepo Escobar5, J. S. Peinado Acevedo2, A. Calle1,5, A. Medina1,5, D. Jaramillo Arroyave1,2,4,5, C. Muñoz2,4, L. A. González2,4, D. Jaramillo Arroyave2,3,4, L. Hernandez2, L. A. González2,4.

1Universidad de Antioquia, Medellín, Colombia; 2Facultad de Medicina Universidad CES, Medellín, Colombia; 3Hospital General, Medellín, Colombia; 4IPS Universitaria, Servicios de Salud Universidad de Antioquia, Medellín, Colombia; 4Hospital Universitario San Vicente Fundación, Medellín, Colombia; 5Grupo de Epidemiología y Bioestadística Universidad CES, Medellín, Colombia

Background: Polyrteritis nodosa (PAN) is a primary systemic vasculitis that is becoming a rare disease in part by the decrease in hepatitis B virus (HBV) infection due to widespread vaccination. It is characterized by a full vast constellation of nonspecific clinical manifestations, which sometimes delays and makes it difficult to diagnose. Still, muscle involvement is a feature that could guide the clinician.

Objectives: to describe the main clinical and laboratory characteristics of patients with PAN and to confirm the frequency of muscle involvement.

Methods: retrospective cross-sectional descriptive study of 23 adult patients diagnosed with PAN between January 2011 and December 2018 in two high complexity hospitals in Medellin-Colombia.

Results: twenty-three patients met ACR 1990 classification criteria for PAN. 52% were men with a median age of 51 (IR 36-60); 78.3% were newly diagnosed, and only two patients (8.7%) had HBV infection. General symptoms (found in 95% of the patients), cutaneous (82%), and articular (56%) were the most frequent manifestations. Among systemic symptoms, myalgia, especially calf pain, was the most common characteristic (78.3%), followed by weight loss (73.9%), fatigue (69.3%), and fever (59.3%). Laboratory findings and severity scores are shown in the table. ANGIOGRAPHY was performed in 27.3% of patients, finding splanchnic (52.2%) and pulmonary (4.3%) microaneurysms (17.4%), stenosis (13%), and renal infarction (4.3%). Twelve patients (61%) had at least one positive biopsy documenting medium-sized artery vasculitis, mainly skin, muscle, nure, or both; 9 (39%) had normal or inconclusive biopsy findings. All patients received high doses of prednisone (50 ± 16 mg); 52.2% required cyclophosphamide, 30.4% azathioprine, 17.4% methotrexate, 8.7% rituximab, 4.3% dapsone and 4.3% plasmapheresis; acetylsalicylic acid was given to half of the patients and only one required antithrombotic therapy for HBV. With treatment, 87% improved; 22.7% had an infection, and 8.7% of patients died.

Conclusion: myalgia was the main characteristics of our PAN patients, especially in calves, and its presence in patients with other general, skin or articular symptoms should raise the suspect of this vasculitis.

References:

Table

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PAN patients (n=23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mean and SD in mg/dL)</td>
<td>6.3 ± 8.5</td>
</tr>
<tr>
<td>ESR (mean and SD in mm/h)</td>
<td>84 ± 38</td>
</tr>
<tr>
<td>CPK (median and IR in U/L)</td>
<td>76 (66)</td>
</tr>
<tr>
<td>FFS (mean)</td>
<td>1</td>
</tr>
<tr>
<td>BVAS (median and IR)</td>
<td>17 (7)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2020-eular.6578

AB0515


F. Muratore1, L. Boiardi1, E. Galli1, G. Pazzolla1, A. Cavazza1, G. Restuccia1, C. Salvatari1, Rheumatology Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 3Pathology Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 4Rheumatology Unit, AUSL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

Background: the classification criteria currently used to define giant cell arteritis (GCA) were developed in 1990 by the American College of Rheumatology

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2020-eular.6596

AB0514

CALF PAIN, KEY POINT IN THE DIAGNOSIS OF POLYARTERITIS NODOSA

J. S. Peinado Acevedo1, M. Calle2,3, A. Medina1, D. Jaramillo Arroyave4,5, A. Vanegas1,2,4,5, L. A. González1, M. Restrepo Escobar1.

1Universidad de Antioquia, Medellín, Colombia; 2Universidad de Antioquia, Medellín, Colombia; 3Hospital Universitario San Vicente Fundación, Medellín, Colombia; 4Hospital General, Medellín, Colombia; 5Grupo de Epidemiología y Bioestadística Universidad CES, Medellín, Colombia

Disclosure of Interests: None declared, Silvia Sartoirelli: None declared, Emanuel Della Torre: None declared, Tommaso Germanò: None declared, Giuseppe Alvise Ramirez: None declared, Luca Moroni: None declared, Adriana Cariddi: None declared, Enrica Bozzolo: None declared, Mona-Rita Yacoub: None declared, Lorenzo Dagna: None declared, Silvia Sartoirelli: None declared, Emanuel Della Torre: None declared, Tommaso Germanò: None declared, Giuseppe Alvise Ramirez: None declared, Luca Moroni: None declared, Adriana Cariddi: None declared.

DOI: 10.1136/annrheumdis-2020-eular.6596

Scientific Abstracts
(ACR), and strongly focus on patients with cranial manifestations. Patients with large-vessel GCA (LV-GCA) have less frequently cranial symptoms and a positive temporal artery biopsy, and are less likely to be captured by the ACR criteria. Glucocorticoid (GC) therapy in patients with GCA, has recognized the concept of GCA as a clinical syndrome, and included patients with cranial and/or polymyalgic symptoms as long as GCA diagnosis was supported by either biopsy or appropriate LV imaging results. However, these inclusion criteria were elaborated by experts and were not validated in patients with GCA.

Objectives: To compare the performance of the 1990 ACR classification criteria and the GIACTA inclusion criteria for the classification of GCA in a single-center cohort of patients with GCA.

Methods: All consecutive patients with a diagnosis of GCA seen between January 2008 and December 2016 in our center were included (GCA cohort). Control cohort consisted of consecutive patients with a negative temporal artery biopsy (TAB) performed in the same time period and a final diagnosis different than GCA. For both study cohort, the final diagnosis was made at the end of the follow-up period by consensus by 2 rheumatologists, who retrospectively evaluated all the medical records from symptoms’ onset to December 2019, last visit, or death. Subjects were classified by each of the different criteria. TABs showing inflammation limited to adventitial or periadventitial small vessels were considered negative for both ACR and GIACTA criteria.

Two-by-two classification tables were generated to estimate sensitivity and specificity, and receiver operating characteristic (ROC) curves with corresponding areas under the curve (AUC) were calculated.

Results: 213 patients were included in the study (75% female, mean age 71.7 years). 55 patients had TAB showing transmural inflammation (TMI); 30 patients had TAB showing inflammation limited to adventitial or periadventitial small vessels (PAI); 67 patients had evidence of LV-GCA at imaging (LV-GCA) and 61 patients had TAB without inflammatory changes (negTAB). 1990 ACR and GIACTA criteria were satisfied respectively by 55 (100%) and 51 (93%) TMI, 18 (60%) and 1 (3%) PAI, 23 (35%) and 31 (46%) LV-GCA and 27 (44%) and none (0%) negTAB patients.

After a median follow-up of 52.6 months, 174 of the 213 (84%) patients had a final diagnosis of GCA (55 TMI, 22 PAI; 67 LV-GCA and 30 negTAB) and the remaining 33 patients had a diagnosis different than GCA (2 PAI and 31 negTAB).

Conclusion: Both 1990 ACR classification criteria and GIACTA inclusion criteria showed a good specificity but a low sensitivity in classifying patients with a clinical diagnosis of GCA from this large monocentric cohort. There is an urgent need for new classification criteria for GCA.

Disclosure of Interests: Francesco Muratore: None declared, Luigi Boiard: None declared, Elena Galli: None declared, GIACtA, a trial of tocilizumab in GCA, has recognized the concept of GCA as a Clinical Syndrome, and Included Patients with Cranial and/or Polymyalgic Symptoms as Long as GCA Diagnosis Was Supported by Either Biopsy or Appropriate LV Imaging Results. However, These Inclusion Criteria Were Elaborated by Experts and Were Not Validated in Patients with GCA.

Table 1.

<table>
<thead>
<tr>
<th>Age (years) ≤ 65</th>
<th>Gender-female(%)</th>
<th>Duration of symptoms (weeks) ≤ 60</th>
<th>Age over 50 %</th>
<th>Bilateral shoulder pain (%)</th>
<th>Abnormal CRP and/or SR (%)</th>
<th>CRP (mg/l) ≤ 36</th>
<th>S (mm/hour) ≤ 12</th>
<th>Morning stiffness</th>
<th>Hip pain or limited range of motion</th>
</tr>
</thead>
<tbody>
<tr>
<td>70.2 ± 8.2</td>
<td>62.6%</td>
<td>12.34 ± 10</td>
<td>98.8%</td>
<td>99.6%</td>
<td>87.8%</td>
<td>4.58 ± 36.8</td>
<td>50.1±26.5</td>
<td>87.9%</td>
<td>66.2%</td>
</tr>
<tr>
<td>70.5± 8.7</td>
<td>56.7%</td>
<td>12.9± 13.4</td>
<td>96.5%</td>
<td>96.5%</td>
<td>94.2%</td>
<td>5.68 ± 41.6</td>
<td>55.1±23.7</td>
<td>91%</td>
<td>70.4%</td>
</tr>
<tr>
<td>25.65 ± 12.1</td>
<td>90.2%</td>
<td>16.4± 4.5</td>
<td>90%</td>
<td>71%</td>
<td>&lt;0.0001</td>
<td>Response to treatment 93.9% n.s.</td>
<td>Response to treatment 93.9% n.s.</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*non-significant

Conclusion: Our study shows that the initial GC dose is significantly higher for PMR patients diagnosed by GPs which may lead to a higher risk of GC related side effects.

References:

Disclosure of Interests: None declared.

AB0016

INITIAL TREATMENT OF POLYMALGYA RHEUMATICA PATIENTS: COMPARISONS BETWEEN GENERAL PRACTITIONERS AND THE RHEUMATOLOGIST.

A. Orva1, N. Svendsen1, P. Lage-Hansen1, N. J. Kock1, A. Diamandopoulos2, S. Chryssides1. 1Hospital of South-West Jutland, University of Southern Denmark, Esbjerg, Denmark; 2Martina Hansen Hospital, Baerum, Norway

Background: Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease at persons > 50 years of age. It is clinically characterized by pain and stiffness in the neck, proximal shoulder, and hip girdle. (1) Glucocorticoid (GC) is the cornerstone of PMR treatment; the use is associated with potentially severe side effects. (2) According to EULAR-ACR recommendations for the management of PMR, treatment should be individualized using the minimum effective GC dose. (2)

An initial prednisolone dose of > 15mg is associated with significantly higher risk for GCs related side effects (1) and GC doses higher than 25mg/day are discouraged because of the high risk of adverse events; furthermore, there is no evidence that such doses are more effective than lower doses (2,3).

In most countries, the vast majority of PMR patients are diagnosed and managed primarily by their General Practitioner (GP) (4)

Objectives: To compare the initial GC dose for PMR patients diagnosed by their GP versus an outpatient rheumatological clinic in Denmark.

Methods: All patients with the diagnosis of PMR in South-West Jutland Hospital, Denmark at the period of 2013 to 2018 were identified from an electronic register. Patients with an already known rheumatic disease before the diagnosis of PMR, GCA symptoms at the diagnosis time or hospitalized at the diagnostic time were excluded. Clinical and paraclinical data were collected from the patient’s electronic journal.

Results: In a period of 6 years, 342 patients with PMR were identified. Of 342 patients 83 were diagnosed by their GP. No significant differences were found regarding demographical, clinical and paraclinical baseline characteristics between the two groups. No differences were identified regarding the treatment response. However the initial prednisone dose in patients diagnosed by the GP’s was significantly higher (p<0,00001) compared to the rheumatological outpatient clinic (Table 1) with an initial dose of ≥25mg at over 50% of newly diagnosed cases (45 patients).

Disclosure of Interests: None declared.

AB0017

USE OF POSITRON EMISSION TOMOGRAPHY IN RHEUMATOLOGY PRACTICE

Ö. Özdemir İskç1, S. Isgören2, A. Yazio1, A. Cefle1, Kocaeli University School of Medicine, Rheumatology, Kocaeli, Turkey; Kocaeli University School of Medicine, Nuclear Medicine, Kocaeli, Turkey

Background: Positron emission tomography (PET), which is widely used in oncology, has recently been used as a guide in the diagnosis of vasculitis and activity monitoring.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2020-eular.6537

Downloaded from http://ard.bmj.com/ on September 21, 2023 by guest. Protected by copyright.